首页> 外文期刊>Angewandte Chemie >DNA-Hybrid-Gated Multifunctional Mesoporous Silica Nanocarriers for Dual-Targeted and MicroRNA-Responsive Controlled Drug Delivery
【24h】

DNA-Hybrid-Gated Multifunctional Mesoporous Silica Nanocarriers for Dual-Targeted and MicroRNA-Responsive Controlled Drug Delivery

机译:DNA杂交门控多功能介孔二氧化硅纳米载体的双目标和MicroRNA响应控制药物输送。

获取原文
获取原文并翻译 | 示例
           

摘要

The design of an ideal drug delivery system with targeted recognition and zero premature release, especially controlled and specific release that is triggered by an exclusive endogenous stimulus, is a great challenge. A traceable and aptamer-targeted drug nanocarrier has now been developed; the nanocarrier was obtained by capping mesoporous silica-coated quantum dots with a programmable DNA hybrid, and the drug release was controlled by microRNA. Once the nanocarriers had been delivered into HeLa cells by aptamer-mediated recognition and endocytosis, the overexpressed endogenous miR-21 served as an exclusive key to unlock the nanocarriers by competitive hybridization with the DNA hybrid, which led to a sustained lethality of the HeLa cells. If microRNA that is exclusively expressed in specific pathological cell was screened, a combination of chemotherapy and gene therapy should pave the way for a targeted and personalized treatment of human diseases.
机译:具有目标识别和零过早释放,尤其是由独家内源性刺激触发的受控和特定释放的理想药物输送系统的设计是一个巨大的挑战。现在已经开发了一种可追踪且以适体为靶标的药物纳米载体。纳米载体是通过用可编程的DNA杂合体封盖介孔二氧化硅涂层的量子点而获得的,药物释放由microRNA控制。一旦将纳米载体通过适体介导的识别和内吞作用传递到HeLa细胞中,过表达的内源性miR-21便成为通过与DNA杂种竞争性杂交来解锁纳米载体的专有密钥,从而导致HeLa细胞持续致死。如果筛选仅在特定病理细胞中表达的微小RNA,则化学疗法和基因疗法的结合应为针对人类疾病的靶向和个性化治疗铺平道路。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号